Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study

1. Pivot, X.
2. Gligorov, J.
3. Müller, V.
4. Barrett-Lee, P.
5. Verma, S.
6. Knoop, A.
7. Curigliano, G.
8. Semiglazov, V.
9. López-Vivanco, G.
10. Jenkins, V.
11. Scotto, N.
12. Osborne, S.
13. Fallowfield, L.